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Over the past two decades there have been signiﬁcant advances in our understanding of
copper homeostasis and the pathological consequences of copper dysregulation. Cumu-
lative evidence is revealing a complex regulatory network of proteins and pathways that
maintain copper homeostasis.The recognition of copper dysregulation as a key pathological
feature in prominent neurodegenerative disorders such as Alzheimer’s, Parkinson’s, and
prion diseases has led to increased research focus on the mechanisms controlling copper
homeostasis in the brain.The copper-transporting P-typeATPases (copper-ATPases), ATP7A
and ATP7B, are critical components of the copper regulatory network. Our understanding
of the biochemistry and cell biology of these complex proteins has grown signiﬁcantly since
their discovery in 1993. They are large polytopic transmembrane proteins with six copper-
binding motifs within the cytoplasmic N-terminal domain, eight transmembrane domains,
and highly conserved catalytic domains. These proteins catalyze ATP-dependent copper
transport across cell membranes for the metallation of many essential cuproenzymes, as
well as for the removal of excess cellular copper to prevent copper toxicity. A key functional
aspect of these copper transporters is their copper-responsive trafﬁcking between the
trans-Golgi network and the cell periphery. ATP7A- and ATP7B-deﬁciency, due to genetic
mutation, underlie the inherited copper transport disorders, Menkes andWilson diseases,
respectively. Their importance in maintaining brain copper homeostasis is underscored by
the severe neuropathological deﬁcits in these disorders. Herein we will review and update
our current knowledge of these copper transporters in the brain and the central nervous
system, their distribution and regulation, their role in normal brain copper homeostasis,
and how their absence or dysfunction contributes to disturbances in copper homeostasis
and neurodegeneration.
Keywords: copper, copper homeostasis, ATP7A, ATP7B, Menkes disease,Wilson disease, occipital horn syndrome,
ATP7A-related motor neuropathy
INTRODUCTION
Copper is indispensable for normal development and function
of the central nervous system (CNS). The copper concentration
of the human adult brain is signiﬁcant, estimated at 7–10% of
total body copper, similar to that of the liver, the major organ
that regulates the copper status of the body (Cartwright and
Wintrobe, 1964; Linder, 1991). Regional variance in brain cop-
per concentrations reﬂects differing metabolic requirements for
copper, which change during development (reviewed in Lutsenko
et al., 2010). Copper is required as a cofactor for numerous critical
enzymes that are involved in vital CNS processes such as respira-
tion, neurotransmitter synthesis, activation of neuropeptides and
hormones, protection from oxidative damage, myelination, pig-
mentation, and iron metabolism among others. The redox cycling
of copper between Cu2+ and Cu+ oxidation states is utilized by
enzymes involved in these processes for catalytic reactions. How-
ever, this redox activity also can lead to elevated reactive oxygen
species (ROS) and corruption of critical proteins by adventitious
binding of copper ions (Halliwell and Gutteridge, 1984). High
oxygen consumption in the brain (20% of total body oxygen),
coupled with low levels of antioxidants and antioxidant enzymes,
and high levels of metal ions, mean the brain is particularly sus-
ceptible toROS-inducedoxidative stress. Hence, precise regulation
of brain copper is essential to ensure appropriate levels and dis-
tribution for the maintenance of brain function, without risking
inadvertent interactions with other cellular components.
Much of what is currently known about brain copper reg-
ulation comes from studies of diseases where copper dysreg-
ulation is associated with neurodegeneration. Menkes disease
(MD; OMIM 309400) is an X-linked inherited disorder with
serious neurological symptoms and neurodegeneration resulting
from severe copper deﬁciency. Occipital horn syndrome (OHS;
OMIM 304150) is an allelic variant of MD with milder neuro-
logical symptoms and predominantly connective tissue defects. In
Wilson disease (WD; OMIM 277900), an inherited, autosomal
recessive copper toxicosis disorder, patients present with hepatic
and neurological symptoms (reviewed in Danks, 1995). There is
mounting evidence that copper dysregulation plays a key role in
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more common neurodegenerative diseases such as Alzheimer’s,
Parkinson’s, Huntington’s, motor neuron, and prion diseases
(reviewed in Scheiber et al., 2013).
The mechanisms of brain copper import, distribution, and
export are nowbeginning to be elucidated. The exchange of copper
between the periphery and the brain is highly regulated by the
brain barriers. The copper concentration of cerebrospinal ﬂuid
(CSF; ∼0.25 μM; Kjellin, 1963; Lentner, 1981) is up to 100-fold
lower than that in the plasma (11–25 μM; Tietz, 1987). In a rat
brain perfusion study that compared copper uptake into brain
capillaries, parenchyma, choroid plexus, and CSF, non-protein
bound free copper ion was the predominant copper species that
entered the brain via both the blood–brain barrier (BBB) and the
blood–CSF barrier (BCB; Choi and Zheng, 2009). The higher rate
of copper transport into the brain parenchyma compared to the
CSF suggests that the BBB is the main site through which copper
enters the brain. Copper inﬂux into the brain parenchyma andCSF
is regulated by copper transporters CTR1, ATP7A, and ATP7B,
which are highly expressed in the brain capillaries and choroid
plexus (Iwase et al., 1996; Qian et al., 1998; Kuo et al., 2006; Niciu
et al., 2006; Choi and Zheng, 2009; Donsante et al., 2010; Davies
et al., 2013).
Signiﬁcant insight into the mechanisms controlling brain cop-
per homeostasis began two decades ago with the identiﬁcation
of the genes encoding the essential copper-transporting ATPases,
ATP7A (Chelly et al., 1993; Mercer et al., 1993; Vulpe et al., 1993)
and ATP7B (Bull et al., 1993; Petrukhin et al., 1993; Yamaguchi
et al., 1993). Mutations in ATP7A and ATP7B underlie MD and
WD, respectively. ATP7A is located on chromosome Xq13.2-13.3
and comprises 23 exons that span approximately 150 kb1. ATP7B
is located on chromosome 13q14.3 and comprises 21 exons that
span approximately 80 kb2. Transcripts of approximately 7.5–
8.5 kb are produced from both genes and contain coding regions
of 4.5 kb, which are translated to produce proteins of 180 and
165 kDa, respectively. ATP7A and ATP7B are members of the P1B-
subfamily of the P-type ATPases. They undergo ATP-dependent
cycles of phosphorylation and dephosphorylation to catalyze the
translocation of copper across cellular membranes. Their struc-
ture and biochemistry was thoroughly reviewed by Lutsenko
et al. (2007). They are highly related in structure and function
with approximately 60% amino acid identity. They have eight
transmembrane domains that form a path through cell mem-
branes for copper translocation; and a large N-terminus with
six metal-binding domains (MBDs), each comprising approxi-
mately 70 amino acids and the highly conserved metal-binding
motif GMxCxxC (where x is any amino acid). Other highly con-
served domains include the intramembrane CPC motif that is
required for copper translocation through the membrane, the
N-domain containing the ATP-binding site, the P-domain con-
taining the conserved aspartic acid residue and the A-domain
comprising the phosphatase domain. Copper-binding together





intracellular location, and copper-induced intracellular trafﬁck-
ing (see below and reviewed in La Fontaine and Mercer, 2007;
Lutsenko et al., 2007; Figure 1).
ATP7A and ATP7B possess dual functions, delivering copper
for incorporation into copper-dependent enzymes, and removal
of excess copper from cells. These functions are largely regulated
by their sub-cellular localization (see below). ATP7A is ubiqui-
tously expressed in extrahepatic cells and tissues, which explains
the systemic defects caused by its absence or inactivation in MD
and points to a house-keeping role for ATP7A. ATP7B has a more
limited expression pattern, with the highest expression level in
the liver, and lower levels in the kidney, placenta, brain, heart,
and lungs (Bull et al., 1993; Tanzi et al., 1993; Vulpe et al., 1993).
This restricted expression suggests more specialized functions for
ATP7B in regulating copper physiology, such as biliary copper
excretion (Terada et al., 1999). ATP7B also has a biosynthetic role,
supplying copper to cuproenzymes such as ceruloplasmin (Terada
et al., 1998). In cells where ATP7B is co-expressed with ATP7A,
it often has a speciﬁc and distinct role (Veldhuis et al., 2009a;
La Fontaine et al., 2010), for example in copper secretion into milk
during lactation (Michalczyk et al., 2008), and in ﬁne-tuning the
intracellular copper balance in the kidney (Linz et al., 2008; Barnes
et al., 2009). The expression of both copper-transporting P-type
ATPases (copper-ATPases) in the brain and the severe neurolog-
ical symptoms that arise from a deﬁciency of either transporter,
suggest that they play key roles in regulating brain copper home-
ostasis. This review will summarize our current knowledge of the
expression, localization, and contribution of ATP7A and ATP7B
to maintaining and managing copper levels within the brain.
EXPRESSION AND LOCALIZATION OF ATP7A AND ATP7B IN
THE BRAIN
ATP7A
TheATP7A gene is transcribed to produce an 8.5 kb transcript that
is expressed in all tissues examined except for the liver (Chelly et al.,
1993; Vulpe et al., 1993). In the mouse brain, the Atp7a transcript
is expressed in the cerebrovascular endothelial (CVE) cells that
form the BBB (Qian et al., 1998), and is strongly expressed in the
choroid plexus (Kuo et al., 1997; Murata et al., 1997; Nishihara
et al., 1998; Choi and Zheng, 2009), a structure that forms the
BCB and regulates the concentration of substances in the CSF
(Figure 2A). Choi and Zheng (2009) further showed that Atp7a is
more highly expressed in the brain barriers (BBB and BCB), the
brain capillaries and choroid plexus, than in brain parenchyma.
Comparing the two barriers, Atp7a mRNA expression is 3.4-fold
higher in the choroid plexus than in the cerebral capillaries. This
observation is consistent with the ﬁnding that the Atp7a protein
levels in the developing and adult mouse brain are highest in the
choroid plexus/ependymal cells of the lateral and third ventricles
(Niciu et al., 2006).
Based on abnormal copper accumulation in cultured astro-
cytes from the macular mouse, a model of MD, Kodama et al.
(1991) proposed that astrocytes play an important role in copper
transport from the blood and CSF toward neurons, and that this
pathway is disturbed in MD and animal models (Figure 2B). Kaler
and Schwartz (1998) later conﬁrmed the expression of mouse and
ratAtp7a in astrocytes from various brain regions (cerebral cortex,
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FIGURE 1 | Schematic diagram of the copper-ATPases, ATP7A andATP7B.
Shown are the highly conserved domains: the N-terminal copper-binding
domain, the phosphatase (A-domain), phosphorylation (P-domain), and
ATP-binding (N-domain) domains; and the motifs and sequences required for
their localization and trafﬁcking. The cylindrical regions labeled 1 - 8 represent
the transmembrane domains.
corpus striatum, and cerebellum). Therefore, ATP7A is postulated
to play a key role in the copper distribution from astrocytes to neu-
rons. Importantly, the successful treatment of MD mouse models
by intravenous administration of copper earlier than postnatal day
7 (P7; Mann et al., 1979) was proposed to be a consequence of the
immaturity of the BBB, which includes astrocytes (Kodama et al.,
1991). This immaturity allows the penetration of copper that is
prevented in these ATP7A-deﬁcient models once development of
the BBB is complete.
Early in situ hybridization studies in mouse brain showed sig-
niﬁcant levels of the Atp7a transcript in the hippocampal CA1
region, the dentate gyrus, the cerebellar granular layer and the
olfactory bulb, and lower levels in the hippocampal CA3 region
and Purkinje neurons (Iwase et al., 1996). Atp7a mRNA was
detected also by RT-PCR in mouse and rat cerebral cortex and
cerebellum, and in isolated rat cerebellar granule neurons (Kaler
andSchwartz,1998). Consistentwith these observations, a detailed
immunohistochemical study by Niciu et al. (2006) demonstrated
the presence of the Atp7a protein in most CNS cell types at P11 in
the developing mouse brain and in the adult brain. In transgenic
mice that overexpressed human ATP7A, the protein is primarily
produced in the CA2 region of the hippocampus, the Purkinje
neurons of the cerebellum, and in the choroid plexus (Ke et al.,
2006). The overexpression of ATP7A resulted in an overall reduc-
tion of brain copper concentrations (Ke et al., 2006), which is
consistent with ATP7A in the choroid plexus functioning to efﬂux
copper back into the circulation (Choi and Zheng, 2009). In more
recent studies of human brain tissue, ATP7A protein levels are
most prominent in the cerebellum and substantia nigra (Davies
et al., 2013). The signiﬁcance of ATP7A expression in these brain
regions is poorly understood.
ATP7A expression is developmentally regulated (Kuo et al.,
1997; Barnes et al., 2005; El Meskini et al., 2005; Niciu et al.,
2006). The widespread expression of Atp7a mRNA in neurons
and ependymal cells during embryonic and postnatal develop-
ment in the mouse (Kuo et al., 1997; Murata et al., 1997) suggests
a house-keeping role for ATP7A in the brain and CNS. Inter-
estingly, Atp7a is not detectable by RT-PCR in embryonic day
20 rat astrocytes, but it is detectable in P3, P8, and adult astro-
cytes (Kaler and Schwartz, 1998). The study by Niciu et al. (2006)
showed that Atp7a protein levels are most abundant in the early
postnatal period, peaking in the neocortex and cerebellum at P4.
From birth (P0) to adulthood, there is a decline in Atp7a lev-
els in most brain regions, and this decline is more pronounced
in the hippocampus and cerebellum than in the hypothalamus
(Niciu et al., 2006). During this postnatal period, despite a gen-
eral decline in Atp7a levels, there is increased Atp7a expression
in CA2 hippocampal pyramidal cells and cerebellar Purkinje neu-
rons. The authors proposed that since theCA2 region is resistant to
epileptogenesis, the increase in CA2 Atp7a levels may contribute
to seizure resistance (Niciu et al., 2006). The observed increase
in Atp7a levels in Purkinje neurons is consistent with signiﬁcant
levels of ATP7A in human cerebellar Purkinje neurons (Davies
et al., 2013), but it is inconsistent with other reports of a post-
natal decline in mouse Atp7a mRNA and protein levels in these
cells (Iwase et al., 1996; Barnes et al., 2005). Although Barnes et al.
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FIGURE 2 | Schematic diagram illustrating the proposed mechanisms
of copper transport across the blood brain barrier (BBB) and blood
cerebrospinal fluid barrier (BCB). (A) Copper transport under
physiological conditions. Copper import into cells is via the major copper
import protein CTR1. The proposed locations and orientation of ATP7A and
ATP7B are shown. ATP7A is expressed in cerebrovascular endothelial cells
that form the BBB but its expression is 3.4-fold higher in the choroid plexus
than in the cerebral capillaries. In both choroid plexus epithelial cells and
capillary endothelial cells of the brain, ATP7A predominantly localizes to the
basolateral membrane. ATP7A facilitates copper transport from the blood
across the BBB to the brain parenchyma. At the choroid plexus, ATP7A
facilitates the removal of excess copper from the brain into the blood.
Therefore, the BCB serves as the main pathway for eliminating excess
brain copper. In contrast, ATP7B is concentrated at the apical membrane.
At the CSF-facing apical membrane of choroid plexus epithelial cells, ATP7B
may contribute to copper transport into the CSF and copper sequestration in
the choroid plexus. Astrocytes are the ﬁrst brain parenchyma cells to
encounter metal ions that cross the BBB and play an important role in copper
transport from the blood and CSF toward neurons. Copper transport in
glutamatergic neurons is depicted. Copper-independent and reversible
trafﬁcking of ATP7A is stimulated by N -methyl-D-aspartate receptor (NMDAR)
activation that leads to Ca2+ inﬂux and is associated with the rapid release
of copper from neurons. The released copper down-regulates NMDAR
activity thus protecting neurons from excitotoxicity. (B) Perturbed copper
transport in Menkes disease due to the absence or inactivation of ATP7A. The
predicted consequences of ATP7A inactivation in relation to copper levels in
brain barrier cells, astrocytes and neurons are shown. Any copper that
reaches the BBB accumulates within endothelial cells leading to reduced
copper transport to the brain parenchyma, astrocytes and neurons. Any
copper that reaches astrocytes also will accumulate. There is reduced copper
transport across the BCB. Excitotoxicity due to impaired synaptic copper
release from glutamatergic neurons, which down-regulates NMDAR
activity, can contribute to seizures and neuronal degeneration in Menkes
disease.
(2005) reported a postnatal switch in the expression of Atp7a from
Purkinje neurons to Bergmann glia in the rodent brain, in human
brain tissue, ATP7A could not be detected in the Bergmann glia
(Davies et al., 2013). This discrepancy may allude to the possibility
that different mechanisms regulate human and rodent cerebellar
copper homeostasis. The increased ATP7A expression in the cere-
bellum may explain the increased sensitivity of this region, and in
particular Purkinje neurons, to copper deﬁciency as observed in
MD (Menkes et al., 1962; Kumode et al., 1993, 1994; Iwase et al.,
1996; Geller et al., 1997; Liu et al., 2005a; Niciu et al., 2006).
In the olfactory system, neuronal Atp7a localization corre-
lates with neuronal maturation. Atp7a is initially concentrated
in neuronal cell bodies at early embryonic stages, then shifts to
the extending axons during the postnatal period (El Meskini et al.,
2005). Atp7a levels peak prior to synaptogenesis, which occurs
postnatally. Similarly, increased expression levels precede synapse
formation following injury-stimulated neurogenesis. Together
with a follow-up study of the mottled brindled mouse model of
MD (MoBr/y), these data suggest a role for ATP7A in axon exten-
sion and synaptogenesis, the absence of which may contribute
to the neurodegeneration evident in MD and its mouse models
(El Meskini et al., 2007).
The increase in ATP7A during the early postnatal period indi-
cates a crucial role for copper during early development, and
particularly in synaptogenesis. This may underlie the critical win-
dow during which some human MD patients and mouse models
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(the mottled mouse mutants) respond favorably to postnatal cop-
per injections, especially when administered in the early postnatal
period (Mann et al., 1979; Fujii et al., 1990; Niciu et al., 2006, 2007;
Tang et al., 2008). Kaler et al. (2008) reported that this successful
copper treatment depends on the presence of a mutant ATP7A
protein with some residual copper transport function. Hence, the
therapeutic efﬁcacy of copper injections may be a consequence of
increased levels of mutantATP7A, albeit with signiﬁcantly reduced
catalytic activity (La Fontaine et al., 1999; Kaler, 2011).
A zebraﬁsh mutant, calamity, with an embryonic-recessive
lethal mutation in the ATP7A ortholog, shows impaired cop-
per homeostasis with absent melanin pigmentation, defective
notochord formation, and neurodegeneration in the hindbrain
region of the developing brain (Mendelsohn et al., 2006; Madsen
et al., 2008). These authors proposed a developmental hierarchy
of copper metabolism, where notochord formation is preferen-
tially preserved during copper limitation, potentially explaining
some of the vascular and neurologic abnormalities observed in
MD. Drosophila has a sole ortholog of ATP7A, DmATP7, which
appears to play an important role in the developing Drosophila
brain (Norgate et al., 2007). It is strongly expressed in the larval
brain at different developmental stages (Burke et al., 2008). Strong
DmATP7A expression is observed in the ventral ganglion but it is
absent from most of the optic lobes (Burke et al., 2008).
ATP7B
Although ATP7B is expressed in the brain (Bull et al., 1993; Tanzi
et al., 1993), its expression patterns and contribution to brain cop-
per homeostasis are less well characterized than that of ATP7A. In
the brain of the developing mouse embryo, Atp7b mRNA cannot
be detected, suggesting that there may be no prenatal expression
or that expression is below the detection limits (Kuo et al., 1997).
Alternatively, consistentwith thepossibility that signiﬁcant expres-
sion begins postnatally, brain copper levels in anAtp7b null mouse
continues to increase slightly throughout adult life (Buiakova et al.,
1999). In a study of Atp7b protein and mRNA distribution in the
rat brain, Atp7b is detected in the hippocampus, the granular cells
of the dentate gyrus and pyramidal cells of the CA1 to CA4 layers,
the glomerular cell layer of the olfactory bulbs, Purkinje neu-
rons of the cerebellum, pyramidal neurons of the cerebral cortex,
and cores of several nuclei (e.g., pontine nuclei and lateral retic-
ular nuclei) in the brainstem (Saito et al., 1999). In these brain
regions, both Atp7b mRNA and protein correlate with copper
distribution as determined by staining with the copper chelator
bathocuproine disulfonic acid (BCS). Based on similar distribu-
tion patterns of cuproenzymes such as dopamine-β-hydroxylase
(DBH) and Cu–Zn superoxide dismutase (Cu–Zn SOD), as well as
abnormal catecholamine synthesis in the Long-Evans Cinnamon
(LEC) rat model of WD (Saito et al., 1996; Okabe et al., 1998),
these authors speculated that ATP7B-mediated control of copper
homeostasis in these brain regions is important in regulating DBH
activity.
In contrast to mouse Atp7a, there is continuous Atp7b expres-
sion in the adult mouse cerebellar Purkinje neurons, and an
age-dependent down-regulation (Barnes et al., 2005). Based on
kinetic studies and experiments in mice lacking Atp7b, these
authors proposed a homeostatic role for ATP7A in maintaining
intracellular copper at a certain level, and a biosynthetic role
for ATP7B mediating the synthesis of copper-dependent enzymes
such as ceruloplasmin (Barnes et al., 2005).
In the human brain, immunohistochemical staining reveals
expression of the ATP7B protein in the visual cortex, anterior
cingulate cortex, body of caudate, putamen, substantia nigra, and
cerebellum, with the most signiﬁcant levels of ATP7B detected in
the cerebellum, anterior cingulated cortex, and caudate putamen
(Davies et al., 2013). Strong staining of ATP7B in Purkinje neu-
rons and not the Bergmann glia is consistent with the ﬁndings in
the adult rat and mouse brains. However, there is no correlation
between ATP7A and ATP7B protein levels and copper levels in the
brain regions investigated (Davies et al., 2013).
FUNCTION AND REGULATION OF THE COPPER-ATPases IN
CNS CELL TYPES
REGULATION OF ATP7A AND ATP7B
Much of what is currently known about the copper-ATPases
derives from studies in peripheral cells and tissues. Emerging stud-
ies of copper transport and the copper-ATPases in the brain and
certain CNS cell types both support our current understanding of
their mechanism of action and regulation, but also provide new
insights into the complexity of copper’s role in the CNS.
ATP7A and ATP7B have a dual role in cells; a biosynthetic
role, delivering copper to the secretory pathway for metallation
of cuproenzymes, and a homeostatic role, exporting excess cop-
per from the cell. Under normal, physiological conditions, ATP7A
and ATP7B are localized at the trans-Golgi network (TGN) where
they provide copper to copper-dependent enzymes synthesized
in the secretory pathway. ATP7A has a role in the metallation
of enzymes such as peptidylglycine α-amidating monooxygenase
(PAM; El Meskini et al., 2003; Steveson et al., 2003), tyrosinase
(Petris et al., 2000; Setty et al., 2008), extracellular SOD3 (Qin
et al., 2005), DBH (Saito et al., 1996), and lysyl oxidase, all of
which are expressed in the CNS (Lutsenko et al., 2010). ATP7A-
mediated copper delivery to lysyl oxidase is proposed based on
similar temporal expressionof these twoproteins in the developing
rat brain and the sensitivity of lysyl oxidase-dependent processes to
ATP7A inactivation as evident in MD and OHS (Royce et al., 1980;
Kuivaniemi et al., 1985; Kaler et al., 1994; Kaler, 1998; Tcha-
parian et al., 2000; Lutsenko et al., 2007). Copper delivery to
apo-ceruloplasmin in hepatocytes (Terada et al., 1998) and mouse
cerebellum(Barnes et al., 2005) ismediated byAtp7b, andbyAtp7a
inmacrophages in response to hypoxia-mediated increased copper
uptake (White et al., 2009).
The key mechanism by which the copper-ATPases regulate cel-
lular copper levels involves alteration of their cellular localization
in response to changes in cytoplasmic copper concentration.When
intracellular copper levels are elevated, ATP7A and ATP7B trafﬁc
from the TGN to the cell periphery to export excess copper from
cells. The copper-induced trafﬁcking of ATP7A was ﬁrst described
in Chinese hamster ovary (CHO-K1) cells (Petris et al., 1996), and
since then, it has been reported in a wide range of non-polarized
(e.g., human ﬁbroblasts, HeLa, and mammary carcinoma cells;
Yamaguchi et al., 1996; Ackland et al., 1997; Dierick et al., 1997;
Francis et al., 1998; La Fontaine et al., 1998a,b; Qi and Byers, 1998)
and polarized cell types (Madin–Darby canine kidney (MDCK),
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mouse enterocytes, Caco-2; Greenough et al., 2004; Monty et al.,
2005; Nyasae et al., 2007). Trafﬁcking of ATP7B also has been
observed in non-polarized hepatoma, human bladder carcinoma,
and CHO-K1 cells (Hung et al., 1997; Yang et al., 1997; Forbes and
Cox, 2000; La Fontaine et al., 2001; Huster et al., 2003), and in
polarized hepatic cells (HepG2 and WIF-B; Roelofsen et al., 2000;
Guo et al., 2005; Cater et al., 2006).
In polarized cells, ATP7A trafﬁcs from the TGN to a rapidly
recycling vesicular pool located near the basolateral membrane
(Monty et al., 2005; Nyasae et al., 2007), whereas ATP7B trafﬁcs to
sub-apical vesicles (Roelofsen et al., 2000; Guo et al., 2005; Cater
et al., 2006). At these locations they sequester and mediate the
export of excess copper. When copper levels return to normal,
ATP7A and ATP7B recycle back to the TGN (Petris and Mercer,
1999; Cater et al., 2006; Nyasae et al., 2007). The trafﬁcking and
recycling of the copper-ATPases requires speciﬁc signal sequences
(Figure 1). For both ATP7A and ATP7B, only MBD 5 or 6 is
necessary and sufﬁcient to mediate copper-stimulated trafﬁcking
from the TGN to the cell periphery (Strausak et al., 1999; Cater
et al., 2004). C-terminal di- and tri-leucine motifs in ATP7A and
ATP7B, respectively, are required for retrograde trafﬁcking of the
proteins to the TGN when copper levels return to normal (Petris
et al., 1998; Cater et al., 2006; Braiterman et al., 2011), and for baso-
lateral targeting of ATP7A in polarized MDCK cells (Greenough
et al., 2004). TGN retention of ATP7A is mediated by a 38 amino
acid sequence contained within transmembrane domain three
(Francis et al., 1998) whereas ATP7A retention at the basolateral
surfacemay require the PDZ-bindingmotif (D1497TAL)within the
C-terminus (Greenough et al., 2004). In ATP7B, a nine amino acid
sequence (F37AFDNVGYE) in the N-terminus is essential for TGN
retention under low copper conditions and for apical targeting in
polarized hepatocytes when copper levels are elevated (Braiterman
et al., 2009). Althoughdetails of the trafﬁckingmachinery involved
in these processes remain to be fully elucidated, interacting part-
ners thatmay play a role includeAIPP1, a PDZdomain-containing
protein that may bind to the PDZ motif in ATP7A (Stephenson
et al., 2005), and dynactin subunit p62 that may be involved in
ATP7B trafﬁcking (Lim et al., 2006b).
In addition to the N- and C-terminal signals that control
the copper-ATPase response to elevated copper, other pro-
cesses also contribute to regulating copper-ATPase activity. They
include, posttranslational modiﬁcations such as transient auto-
phosphorylation at the invariant aspartate residue (D1044KTGT;
Figure 1) to form an acyl-phosphate intermediate, a process that
is characteristic of the P-type ATPase catalytic cycle (Voskoboinik
et al., 1998, 2001a,b; Petris et al., 2002; Tsivkovskii et al., 2002;
Cater et al., 2007), copper-stimulated phosphorylation by kinases
(Vanderwerf et al., 2001; Voskoboinik et al., 2003; Veldhuis et al.,
2009b), and protein interactions. ATOX1 was the ﬁrst protein
shown to interact in a copper-dependent manner with the N-
terminal domain of both proteins for delivery of copper to the
secretory pathway (Hamza et al., 1999; Larin et al., 1999). MBD
1–4 is most important for this interaction, in particular MBD
2 and 4 (Strausak et al., 2003; Walker et al., 2004; Achila et al.,
2006). This is supported by studies in the Atox1 null mice, which
demonstrated a critical requirement for Atox1 in Atp7a function
and copper homeostasis (Hamza et al., 2001, 2003). A 45 kDa
isoform of the promyelocytic leukemia zinc ﬁnger (PLZF) protein,
a transcriptional repressor of Hox genes, interacts with the C-
terminus of ATP7B (Ko et al., 2006). Both proteins co-localized
within the TGN, and based on experiments in HepG2 cells and
Drosophila, this interaction is proposed to have a role in regulating
ERK signal transduction. However, the functional consequences
of these associations remain to be elucidated. The glutaredoxin1
(GRX1)/glutathione (GSH) system may play a key role in regulat-
ing the trafﬁcking and activity of the copper-ATPases by regulating
their redox state through glutathionylation and deglutathionyla-
tion by GRX1 (Lim et al., 2006a; Singleton et al., 2010). GRX1
protects proteins from oxidative damage (Mieyal et al., 2008), and
it is expressed throughout the brainwith highest activity in the hip-
pocampus, cortex and midbrain (Balijepalli et al., 1999; Ehrhart
et al., 2002; Aon-Bertolino et al., 2011). Hence, GRX1/GSH may
preserve the integrity and function of ATP7A and ATP7B during
oxidative stress, which accompanies neuropathological processes.
Clusterin (ApoJ) and COMMD1 regulate the degradation of
misfolded and mutant copper-ATPases via the lysosomal and pro-
teasomal pathways, respectively (de Bie et al., 2007; Materia et al.,
2011, 2012).
ROLE OF THE COPPER-ATPases IN CNS CELL TYPES
Information on the activity of the copper-ATPases in speciﬁc CNS
cell types is limited and somewhat fragmentary, but emerging
evidence is revealing speciﬁc roles for ATP7A and ATP7B in brain
and CNS copper homeostasis. Peripherally, ATP7A and ATP7B
mostly have cell type-speciﬁc expression patterns and where co-
expressed in certain cells and tissues (e.g., kidney, placenta, and
mammary gland), they have distinct roles (reviewed in La Fontaine
and Mercer, 2007 andVeldhuis et al., 2009a). Similarly in the CNS,
ATP7A and ATP7B may be uniquely expressed in certain cell types
and co-expressed in others.
Choroidal epithelial cells and brain capillary endothelial cells
The BBB and BCB regulate the movement of copper between the
brain and peripheral circulation. In both choroid plexus epithelial
cells and capillary endothelial cells of the brain, ATP7A predomi-
nantly localizes to the basolateral membrane, which is consistent
with its location in other polarized epithelial cell types such
as intestinal enterocytes (Monty et al., 2005; Nyasae et al., 2007;
Davies et al., 2013). In contrast,ATP7B is concentrated at the apical
membrane, again consistent with its localization in polarized hep-
atocytes (Roelofsen et al., 2000; Guo et al., 2005; Cater et al., 2006;
Davies et al., 2013). This distinct membrane localization of ATP7A
and ATP7B combined with their discrete enzyme kinetics may be
a mechanism to ensure strict control over copper transport across
theBCBandBBB (Tsivkovskii et al., 2002; Barnes et al., 2005;Hung
et al., 2007). The kinetically slower ATP7B at the CSF-facing api-
cal membrane of choroid plexus epithelial cells may explain the
slower rate of copper transport into the CSF relative to the choroid
plexus copper uptake rate, and may contribute to copper seques-
tration in the choroid plexus (Barnes et al., 2005, 2009; Choi and
Zheng, 2009). In contrast, the basolateral location of the kinet-
ically faster ATP7A facilitates the removal of excess copper from
the brain into the blood (Davies et al., 2013). This arrangement
of the copper-ATPases is similar to that in other tissues such as
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the mammary epithelium or the kidney where ATP7A serves to
protect from copper excess while ATP7B serves a biosynthetic role
(La Fontaine and Mercer, 2007; Veldhuis et al., 2009a). There-
fore, the BCB serves as the main pathway for eliminating excess
brain copper (Figure 2). In a further study that utilized cultured
choroidal epithelial Z310 cells, siRNA-mediated knockdown of
ATOX1 andATP7A resulted in increased cellular copper retention,
conﬁrming the involvement of ATP7A in copper transport across
the choroid plexus and hence in regulating copper homeostasis of
the CSF (Monnot et al., 2012). The BBB, which regulates copper
inﬂux into the brain, has lower levels of ATP7A at the basolateral
surface of brain capillary endothelial cells to enable rapid but lim-
ited transport of copper into the brain to accommodate sudden
changes in brain copper concentration (Choi and Zheng, 2009).
Astrocytes
Astrocytes play a pivotal role in brain copper homeostasis. They
are strategically sandwiched between endothelial cells of the BBB
and neurons, hence, they are the ﬁrst brain parenchyma cells to en-
counter metal ions that cross the BBB. Astrocytes are able to efﬁ-
ciently take up and store copper, and with greater resistance to
copper-induced toxicity, they protect neurons fromcopper toxicity
(reviewed in Tiffany-Castiglioni et al., 2011; Scheiber and Drin-
gen, 2012). Atp7a has been detected in rodent astrocytes in culture
and in brain tissue (Qian et al., 1997; Barnes et al., 2005; Niciu
et al., 2007; Scheiber et al., 2012). These studies implicate Atp7a in
copper export from astrocytes, which is consistent with the early
observations by Kodama et al. (1991) of copper accumulation in
astrocytes of themacularmouse (Figure 2B). In astrocytes, similar
to peripheral cell types, Atp7a localizes to a perinuclear region and
undergoes copper-responsive trafﬁcking between the TGN and
the cell periphery. Therefore, it was proposed that Atp7a mediates
copper export from astrocytes, which is time-, concentration- and
temperature-dependent (Scheiber et al., 2012). However, in con-
trast to previous studies, copper export from cultured astrocytes
is non-saturable and does not follow the established Michaelis–
Menten kinetics forATP7A-dependent copper transport (Scheiber
et al., 2012). Therefore, additional ATP7A-independent mecha-
nisms may be involved in copper export from astrocytes. The rate
of copper export is proportional to the increase in copper content
after copper exposure, which led Scheiber et al. (2012) to pro-
pose that the copper export rate is determined by the trafﬁcking
or fusion of Atp7a-containing vesicles with the plasma mem-
brane, rather than by ATP7A-mediated transport of copper into
vesicles.
Neurons
Cerebellar Purkinje neurons are highly sensitive to copper deﬁ-
ciency during development (Lyons and Prohaska, 2009). In the
human brain, ATP7A and ATP7B are co-expressed in Purkinje
neurons (Davies et al., 2013), and in the mouse brain, for a post-
natal period of up to 2 weeks (Barnes et al., 2005). Co-expression
of both copper-ATPases may be a mechanism to achieve a deli-
cate balance of copper that is critical to cerebellar development
and function. Based on the faster kinetics of copper transport by
Atp7a relative toAtp7b, a homeostatic role is proposed forAtp7a in
maintaining the intracellular copper level, and a biosynthetic role
for Atp7b to mediate the synthesis of copper-dependent enzymes
such as ceruloplasmin (Barnes et al., 2005).
Hippocampal ATP7A plays a pivotal role in learning and
memory. In mature rat primary hippocampal neurons, Atp7a
undergoes both copper-dependent and -independent redistribu-
tion from the TGN to dendrites and axons (Schlief et al., 2005).
The study by Schlief et al. (2005) provides the ﬁrst evidence of
copper-independent and reversible trafﬁcking of Atp7a that (i)
is stimulated by N-methyl-D-aspartate (NMDA) receptor acti-
vation, (ii) requires Ca2+ inﬂux through the NMDA receptor,
and (iii) is associated with the rapid release of copper from hip-
pocampal neurons (Figure 2A). The inability to detectAtp7a at the
cell surface prompted the suggestion that copper may be released
by exocytosis from vesicles once Atp7a has recycled back to the
TGN. This possibility is consistent with the rapid efﬂux of cop-
per following NMDA receptor activation. The authors suggest
that NMDA receptor activation-mediated trafﬁcking of copper-
loaded, ATP7A-associated vesicles provides a readily available and
releasable pool of copper following Ca2+ inﬂux (Schlief et al.,
2005). In the hippocampus, following neuronal depolarization,
about 15 μM of copper is released into the glutamatergic synaptic
cleft from synaptic vesicles (Rajan et al., 1976; Hartter and Barnea,
1988; Kardos et al., 1989; Barnea et al., 1990; Hopt et al., 2003).
While the physiological signiﬁcance of synaptic copper release is
not yet clear, it is proposed that copper down-regulates NMDA
activity through redox processes that involve S-nitrosylation of
speciﬁc cysteine residues within NMDA subunits NR1 and NR2A,
thus protecting hippocampal neurons from excitotoxicity (Schlief
et al., 2006). These ﬁndings link ATP7A and copper with mod-
ulating memory and learning processes that depend on precise
regulation of NMDA receptor activity (Schlief et al., 2006). In MD,
deﬁciencies in both brain copper and ATP7A activity will prevent
copper release, thus impairing NMDA receptor modulation. The
subsequent NMDA-mediated excitotoxicity may contribute to the
pathological features, seizures and neuronal degeneration, that are
characteristic of MD (Schlief et al., 2006). In Alzheimer’s disease
(AD), the combination of increased copper andAβ [the amyloido-
genic cleavage product of the amyloid precursor protein (APP)]
in the synaptic cleft may promote the formation of neurotoxic
Aβ-copper oligomers contributing to the neuropathology of AD.
Motor neurons
The recent identiﬁcation of a new ATP7A-related distal heredi-
tary motor neuropathy (dHMN), caused by mutations in ATP7A
(see below), has drawn attention to the role of ATP7A in motor
neurons (Kennerson et al., 2010; Yi et al., 2012). The cell bod-
ies of motor neurons are located within the anterior horn of the
spinal cord, and their axons extend for long distances to distal limb
muscles. Hence, both the CNS and peripheral nervous system are
affected in motor neuron disorders (Harding and Thomas, 1980).
In undifferentiated NCS-34 cells (a motor neuron-enriched cell
line), Atp7a is localized at the TGN and trafﬁcs to the cell periph-
ery with elevated copper, as it does in most other cell types. In
differentiated NSC-34 cells, Atp7a can be detected along the full
length of Tau-1-positive neuritic projections, with localization to
the axonal membrane when copper levels are elevated (Yi et al.,
2012). Based on the data presented, ATP7A was postulated to
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trafﬁc along axons, and to mediate copper release from the axonal
membrane of motor neurons.
Retinal pigment epithelium
Retinal degeneration is observed in both MD and WD (Ferreira
et al., 1998). The essential requirement for copper and ATP7B
for retinal structure integrity is underscored by reduced thick-
ness of total macula as well as ganglion cell and inner plexiform
layer in WD patients. Up to 50% of WD patients have abnormal
visual evoked potentials (VEPs; Albrecht et al., 2012). Immuno-
histochemical studies of mouse and human retina identiﬁed the
presence of ATP7A in the retinal pigment epithelium (RPE),
outer plexiform layer (OPL), and ganglion cell layer (GCL) of the
BALB/c mouse retina (Krajacic et al., 2006). In contrast, ATP7B
expression is restricted to the RPE. Within the RPE, both copper-
ATPases localize to a perinuclear region that overlapwith TGNand
Golgi markers, consistent with their biosynthetic role in delivering
copper to tyrosinase for melanogenesis, and to the iron homeo-
static proteins ceruloplasmin and hephaestin. Increased copper
levels trigger a redistribution of ATP7B to a diffuse cytoplasmic
compartment in an immortalized human RPE cell line.
Microglia
Activated microglial cells concentrate at sites of neuronal dam-
age and inﬂammation. Atp7a expression is elevated in activated
microglia surrounding Aβ plaques in the TgCRND8 transgenic
mouse model of AD (Zheng et al., 2010). Data from cultured
mouse BV-2 microglial cells suggest Atp7a expression and trafﬁck-
ing is responsive to stimulation by the pro-inﬂammatory cytokine
interferon-gamma (IFN-γ). Concomitant copper accumulation
due to upregulation of the copper import protein, Ctr1 and cop-
per uptake, suggests a role for copper in the pro-inﬂammatory
pathway. Furthermore, the IFN-γ-stimulated ATP7A redistribu-
tion differs from that induced by copper, and appears to mediate
copper sequestration in cytoplasmic vesicles rather than copper
export. This mechanism is postulated to represent a protective
mechanism by activated microglia at sites of amyloidogenesis to
reduce aberrant copper-Aβ interactions in the extracellular milieu
(Zheng et al., 2010).
Pineal gland
Pineal night-speciﬁc ATPase (PINA) is a novel splice variant of
ATP7B, lacking theN-terminalMBDs and the ﬁrst four transmem-
brane domains. It has a predominant nocturnal expression in the
pineal gland and retina, under the control of the retina-speciﬁc
protein, cone rod homeobox (CRX; Li et al., 1998). Despite a large
N-terminal truncation, PINA retains a weak copper transport
function in a Saccharomyces cerevisiae ccc2 complementation
assay (Borjigin et al., 1999). This ﬁnding implicates a yet-to-be-
deﬁned role for PINA-mediated copper metabolism in pineal and
retinal circadian function (Li et al., 1998; Borjigin et al., 1999).
Neuroblastoma cells
Neuroblastoma cells have a high demand for copper for prolif-
eration. High concentrations of copper in neuroblastoma cells
are likely achieved via down-regulation of ATP7A expression and
thus, reduced copper efﬂux. Retinoid treatment of neuroblastoma
cells causes transcriptional upregulation of ATP7A and an increase
in ATP7A protein levels (Liu et al., 2005b; Bohlken et al., 2009).
Ectopic expression of the retinoic acid receptor β2 subtype
(RARβ2) also induces ATP7A expression, which is associated a
growth inhibitory effect. Conversely, knockdown of ATP7A is
associated with reduced copper efﬂux and increased viability of
retinoid-treated cells. These data support a model where malig-
nant neuroblastoma cells have a high copper-dependency for via-
bility and proliferation, and copper depletion by retinoid/RARβ2-
induced ATP7A upregulation offers therapeutic beneﬁt (Bohlken
et al., 2009).
FUNCTIONAL CONTRIBUTION OF ATP7A AND ATP7B TO
BRAIN COPPER HOMEOSTASIS
An appreciation of the role of ATP7A and ATP7B in brain cop-
per management derives largely from the functional consequences
of their absence or inactivation in the genetically inherited dis-
eases, MD, OHS, WD, and the recently identiﬁed ATP7A-related
motor neuropathy. The importance of their correct function is
also emerging in the context of other neurological diseases where
there is perturbed copper metabolism, such as the prion diseases
and AD. Our current understanding of the copper-ATPase contri-
bution to brain copper homeostasis and the consequences of their
absence or impaired function is summarized below.
MENKES DISEASE AND OCCIPITAL HORN SYNDROME
The widespread expression of ATP7A accounts for the systemic
defects that arise from mutation of this gene in MD. This X-linked
disease presents in males within the ﬁrst few months of life, and
in severe cases, it is fatal within 2–3 years. The severity of the
clinical presentation can vary, but commonly includes abnormal
neurodevelopment, seizures associated with cerebral atrophy and
dysmyelination, a range of connective tissue and vascular abnor-
malities, fragile bones, an unusual kinky hair structure (pili torti),
hair and skin pigmentation defects and failure to thrive (reviewed
inDanks, 1995; Kaler, 2011). These symptoms arise from impaired
intestinal copper absorption leading to systemic copper deﬁciency
and consequently, reduced activity of critical copper-dependent
enzymes. Paradoxically, copper retention is evident in certain tis-
sues exposed to the limited copper that reaches them and in MD
patient skin ﬁbroblast cells (Camakaris et al., 1980; Danks, 1995).
Histochemical analysis of brain tissue from affected MD patients
revealedneurodegeneration in the cerebral cortex, cerebellum, and
hippocampus (Okeda et al., 1991) where ATP7A is enriched (see
above).
Occipital horn syndrome is also caused by mutations inATP7A,
but it is a milder disease with primarily connective tissue defects
and moderate neurological symptoms (Kaler et al., 1994; Kaler,
1998). Causative mutations are often splice site mutations that
result in reduced levels of normal ATP7A mRNA (reviewed in
Kaler, 2011). The milder phenotype suggests that sufﬁcient resid-
ual functional ATP7A is produced, but the prominent connective
tissue defects indicate that copper delivery to lysyl oxidase is
severely disrupted (Kaler, 2011; Scheiber et al., 2013).
The neurological symptoms of MD and OHS have been
attributed to impaired ATP7A-mediated copper transport across
the BBB (Figure 2B), leading to deﬁciencies of enzymes such
as cytochrome c oxidase, SOD1, BDH, PAM, lysyl oxidase, and
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tyrosinase, some of which require ATP7A for metallation in the
TGN.The bioactivity of manyneuropeptides is dependent on their
amidation by PAM,while DBH is important for the production of
the neurotransmitter norepinephrine from dopamine (reviewed
in Lutsenko et al., 2010; Kaler, 2011). However, impairment of
other ATP7A-mediated functions also is likely to contribute to
the neurodegeneration in MD. For example, excitotoxicity due to
impaired synaptic copper release, which down-regulates NMDA
receptor activity, can contribute to seizures and neuronal degen-
eration (Schlief et al., 2005, 2006; Figure 2). In MoBr/y mice, the
absence of a functional ATP7A protein results in degeneration of
Purkinje neurons, cytoskeletal abnormalities, and impaired synap-
togenesis and axonal outgrowth (Niciu et al., 2006; El Meskini
et al., 2007; Niciu et al., 2007).
There are a number of MD mouse models. As noted in the
preceding sections, these mouse models have been invaluable in
revealing insights into the critical role of ATP7A in the brain.
The mottled mice are a series of mouse mutants with muta-
tions in the murine ortholog of ATP7A. They exhibit a range of
phenotypes that recapitulate the variable clinical severity of the
human disease (Levinson et al., 1994; Mercer et al., 1994; Mercer,
1998). The MoBr/y mouse model resembles most closely classi-
cal MD with neurological deﬁcits and early postnatal lethality.
This mouse expresses close to normal levels of Atp7a that has
severely reduced copper transport activity due to an in-frame
deletion of six nucleotides, leading to the loss of highly con-
served amino acids A799 and L800 (Grimes et al., 1997). Studies
in this mouse elegantly demonstrated the importance of Atp7a
in supplying copper to PAM for the amidation of neuropeptides
(Steveson et al., 2003), in axon extension and synaptogenesis, and
in compensatory mechanisms to facilitate copper transport across
the BBB. The latter includes upregulation of the mutant Atp7a
in endothelial cells, as well as increased association of MoBr/y
astrocytes and microglia with the BBB, and these mechanisms
possibly contribute to the effectiveness of early copper treatment
(El Meskini et al., 2005, 2007; Niciu et al., 2007). The severe copper
deﬁciency in the brain of MoBr/y mice can be rescued by trans-
genic expression of the human ATP7A. Expression of the ATP7A
transgene was detected in the cerebellar Purkinje cell layer, the
CA1 and CA2 regions of the hippocampus, the mitral layer of the
olfactory bulb, the vascular endothelium, and the choroid plexus,
but it could not be detected in astrocytes (Llanos et al., 2006).
The gene correction signiﬁcantly improved the survival of the
ATP7A-expressing transgenic MoBr/y mice compared with non-
transgenic animals. Furthermore, a recent study demonstrated
rescue of neonatal MoBr/y mice following lateral ventricle injec-
tions of adeno-associated virus serotype 5 (AAV5) harboring a
truncated ATP7A cDNA, in combination with copper treatment
(Donsante et al., 2011). The authors proposed different effects of
the two treatments: the copper injections increased the amount
of brain copper available to levels that were 25–50% of the wild
type, while the AAV5 gene delivery improved copper utilization.
This was associated with enhanced activity of DBH and correction
of brain pathology (Donsante et al., 2011). These ﬁndings further
illustrate the critical role of copper and ATP7A for brain function
andhighlight thepotential for gene therapy in the treatment of MD
patients.
ATP7A-RELATED MOTOR NEUROPATHY
Recently, missense mutations in ATP7A were found to cause a
form of dHMN (Kennerson et al., 2010; Yi et al., 2012), which
represents the third clinical phenotype associated with mutations
in ATP7A. dHMNs are a clinically and genetically heterogeneous
group of diseases characterized by lower-motor neuron weakness
and muscular atrophy (Rossor et al., 2012). Merner et al. (2010)
proposed that a common factor in the disease mechanism may
be altered copper homeostasis. The phenotype of ATP7A-related
motor neuropathy is clinically distinct from that of MD,with vari-
able age of onset that ranges from theﬁrst to the sixth decade of life,
no overt abnormalities of copper metabolism, and typically distal
muscle weakness and atrophy of the lower extremities leading to
hand and foot deformities (Kaler, 2011). Nerve conduction stud-
ies suggest that the disease causes gradual degeneration of motor
neuron axons in the limbs, beginning in the distal portion and
progressing toward the cell body (Takata et al., 2004; Kennerson
et al., 2009,2010). The late-onset nature of the disease suggests that
these mutations in ATP7A have subtle effects on ATP7A function
that can take years to manifest clinically.
The missense mutations within ATP7A that result in T994I
and P1386S substitutions were identiﬁed in two families with
multiple affected males (Kennerson et al., 2010; Yi et al., 2012).
These mutations are outside of the conserved functional domains
and they cause abnormal ATP7A trafﬁcking, affecting speciﬁ-
cally motor neuron function. An abnormal interaction between
ATP7A (T994I) and valosin-containing protein (p97/VCP) was
demonstrated, the latter, an ATPase with functions that include
vesicular trafﬁcking and protein degradation by the ubiquitin
(Ub)-proteasome system (UPS; Watts et al., 2004; Yi et al., 2012).
Mutations in p97/VCP are also associated with other diseases that
involve motor neuron degeneration (Watts et al., 2004). The sig-
niﬁcance of this interaction in mediating the disease phenotype
awaits further investigation. Potential mechanisms that can lead to
axonal degeneration as a result of these ATP7A mutations include
copper deﬁciency, oxidative damage from mislocalized copper,
and/or slowed synaptic copper release, resulting in inefﬁcient
down-regulation of the NMDA receptor and hence excitotoxicity
leading to neuronal damage and axonal dieback.
WILSON DISEASE
In a signiﬁcant proportion of WD patients, neurodegeneration
and neurological presentation reveals an important role forATP7B
in maintaining neuronal copper homeostasis. WD manifests pri-
marily in the liver and brain. Mutations that inactivate ATP7B
lead to impaired biliary copper excretion (Terada et al., 1999) and
consequently, hepatic copper overload, apoptotic cell death, liver
damage, and spillage of copper into the plasma and CSF (Weisner
et al., 1987; Kodama et al., 1988; Strand et al., 1998; Gitlin, 2003).
Hence, copper also accumulates in extrahepatic tissues, notably
the brain, kidneys, and cornea (Danks, 1995; Culotta and Gitlin,
2001).
Approximately 40–50% of WD cases present with neurological
symptoms and these patients typically have a later onset than those
with the liver disease, presenting in the second or third decade
(Das and Ray, 2006; Gouider-Khouja, 2009). Although ATP7B is
expressed in several brain regions, brain copper accumulation in
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WD appears to be secondary to the liver disease, because it can be
reversed by transplantation (Emre et al., 2001; Schumacher et al.,
2001). The psychiatric symptoms also are reversible with chelation
therapy (Madsen and Gitlin, 2007). The main areas of the brain
affected in WD patients include the thalamus, subthalamic nuclei,
brainstem, cerebellum, and frontal cortex (Das and Ray, 2006).
The precise mechanisms mediating neuronal injury in WD are
not clear, but potentially involve increased extracellular copper
combined with impaired copper homeostasis in those regions of
the brain suffering loss of ATP7B function. For example, impaired
DBH synthesis may explain the predominant abnormalities of the
basal ganglia that result in Parkinsonian symptoms such as rigidity
and tremor (Das and Ray, 2006; Pfeiffer, 2007).
The toxic milk mouse (tx) and the LEC rat are mouse models
of WD that harbor a point mutation (Theophilos et al., 1996) or
deletion (Wu et al., 1994), respectively, in Atp7b. Studies of the
neurological symptoms and neurodegenerative processes in these
models have been lacking until recently. One study found that
despite an increase in brain copper levels of the tx mouse, there
are no neurological or behavioral symptoms (Allen et al., 2006).
In contrast, a more recent study reported copper deposition in the
striatum and hippocampus of tx mice associated with an inﬂam-
matory response in these tissues, as well as motor and cognitive
disturbances and impaired spatial memory (Terwel et al., 2011).
The reason for the discrepancy between these two studies is not
clear but may relate to the genetic background of the tx mice used.
ALZHEIMER’S DISEASE
Alzheimer’s disease is a progressive neurodegenerative disorder
occurring late in life. Patients suffer memory loss and cognitive
decline. Key pathological hallmarks include intra- and extracel-
lular proteinaceous deposits (senile plaques comprising the Aβ
peptides derived from the processing of APP and neuroﬁbrillary
tangles (NFTs) composed of hyperphosphorylated tau). The role
of copper inAD is gaining prominencewith the discoveries that: (i)
it is increased and/or mis-localized in the AD brain; (ii) enriched
in extracellular plaques; (iii) deﬁcient in Aβ plaque neighboring
brain regions; and (iv) disease-linked proteins, APP, Aβ, tau, and
BACE1, are copper-binding proteins with key roles in brain metal
regulation (reviewed in Kozlowski et al., 2009; Hung et al., 2010).
These observations and ﬁndings of dysregulation of other met-
als such as iron and zinc have led to the “metal theory of AD”
with the coining of the term, “metallostasis.” This represents the
fatigue of brain metal regulation and distribution, leading to Aβ
aggregation anddeposition, intraneuronal iron accumulation, and
consequently, oxidative injury and neurodegeneration (Roberts
et al., 2012; Bush, 2013).
Genetic analysis of AD patients and healthy controls uncov-
ered ATP7B as a genetic risk factor for AD. A number of single
nucleotide polymorphisms (SNPs) in ATP7B are associated with
increased risk for AD (Bucossi et al., 2011, 2012; Squitti et al.,
2013). These changes occur in either a MBD, the ATP-binding N-
domain or transmembrane domains, which may negatively affect
ATP7B function in relation to metal-binding, ATP hydrolysis or
copper translocation across the membrane. SNPs in the trans-
membrane domains present the strongest association for AD risk
(Squitti et al., 2013). These observations further support a crucial
role for ATP7B in maintaining brain copper homeostasis and a
potential role in AD pathogenesis. In contrast to these observa-
tions, transgenic APP mice (CRND8) that are homozygous for the
txJ mutation, and therefore lacking a functional ATP7B protein,
exhibit elevated brain copper levels, but a markedly reduced num-
ber of amyloid plaques and decreased plasma Aβ levels (Phinney
et al., 2003). The authors postulated that the mechanism of this
beneﬁcial effect of the txJ mutation involves increased clearance
of peripheral Aβ pools. Alternatively, elevated intracellular copper
due to the txJ mutation may correct the copper-deﬁcient pheno-
type of the CRND8 mice. The copper-induced retention of APP
at the cell surface, leading to reduced Aβ production and interac-
tion with copper in lipid rafts may explain the decrease in Aβ and
amyloid plaques (Hung et al., 2009; Acevedo et al., 2011).
APOE and CLUSTERIN (APOJ) polymorphisms represent the
strongest and third strongest genetic risk factors for AD, respec-
tively (Bertram et al., 2007). The encoded proteins have long
associations with AD (Mahley et al., 2006; Nuutinen et al., 2009;
Yu and Tan, 2012). ApoE and clusterin are well-known for their
function as secreted extracellular chaperones with key roles in
lipid transport. They have neuroprotective functions, coopera-
tively regulating the deposition and clearance of Aβ (DeMattos
et al., 2004; Wilson et al., 2008). In humans, there are three com-
mon APOE alleles, ε2, ε3, and ε4. APOE-ε4 confers increased
risk for AD. The presence of APOE-ε4 in WD patients with the
common H1069Q mutation in ATP7B is associated with an ear-
lier onset of symptoms (Litwin et al., 2012). In contrast, APOE-ε3
is associated with a signiﬁcant delay in the onset of WD symp-
toms compared with APOE-ε4 carrying patients (Schiefermeier
et al., 2000; Wang et al., 2003). This difference may be linked to
the isoform-speciﬁc antioxidant activity of the ApoE isoforms
(Miyata and Smith, 1996). ApoE4 is less effective than
ApoE2/ApoE3 as an antioxidant, which may explain the greater
susceptibility of ApoE4 patients to copper toxicity. While the exact
mechanism remains unclear, these studies suggest a role for ApoE
in copper regulation and in inﬂuencing WD phenotypes.
We recently demonstrated that clusterin interacts with ATP7A
and ATP7B, and this interaction appears to facilitate the degra-
dation of misfolded copper-ATPase molecules predominantly via
the lysosome (Materia et al., 2011, 2012). Both MD and WD
exhibit a high degree of clinical variability (de Bie et al., 2007;
Tumer and Moller, 2009), with reports of identical mutations,
even among siblings, conferring variable clinical expression (Duc
et al., 1998; Borm et al., 2004). Hence, these observations impli-
cate other factors in determining the clinical phenotype. Based
on functional similarities between clusterin and ApoE, the asso-
ciation between ApoE isoforms and WD onset, and the role of
clusterin in copper-ATPase degradation, these molecules poten-
tially could play a role in modifying the expression of neurological
disease such as AD, MD, and WD. Conceivably, genetic variations
in the clusterin and ApoE alleles, together with environmental fac-
tors, could contribute to the variability in the clinical expression of
MD and WD.
PRION DISEASE
Prion diseases are characterized by the continual conformational
change of the normal prion protein (PrPC) to an infectious,
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protease-resistant, β-sheet-rich form of the protein (PrPSc;
Prusiner, 1982). The resultant toxic PrPSc aggregates can disrupt
axonal transport and synaptic transmission and/or trigger apop-
tosis, leading to the neurodegenerative pathologies that are collec-
tively termed transmissible spongiform encephalopathies (TSE)
(reviewed in Davies and Brown, 2013).
Prion protein is amembrane glycoproteinwith fourN-terminal
octameric repeats and a nearby site that binds copper (Hornshaw
et al., 1995a,b; Brown et al., 1997). This protein is ubiquitously
expressed but enriched in neurons and concentrated at the synapse
(Sales et al., 1998). Its normal physiological role still remains to be
fully elucidated but insight into the cell biology and biochemical
properties of PrPC is revealing some clues regarding its function.
Various studies have demonstrated that copper-binding induces
PrPC internalization (Davies and Brown, 2013) prompting the
suggestion that PrPC may be involved as a receptor for copper
uptake or efﬂux (Brown and Harris, 2003). More recently, You
et al. (2012) conﬁrmed previous ﬁndings that copper modulates
NMDA receptor activity. They further demonstrated that this
occurs through a copper-dependent interaction between PrPC and
the GluN1 subunit, which reduces glycine afﬁnity for the receptor,
thus suppressing its activity. The role of ATP7A-mediated synap-
tic copper release may be important in this context but whether it
plays a direct role in PrPC-copper interactions is not clear.
In contrast to the beneﬁcial role of copper in PrPC function
noted above, other studies reported that copper binding to PrPC
increases its conversion to PrPSc, and that copper chelation delays
the onset of prion disease (Sigurdsson et al., 2003). In support of
these studies, disruption of copper homeostasis due to a hypo-
morphic mutation in ATP7A delays the onset of prion disease in
mice (Siggs et al., 2012). Copper levels in the brain are reduced by
60% and the amount of the disease-causing PrPSc is signiﬁcantly
lower than that of the controls. The controversies over the role of
copper in PrPC function and prion disease remain to be clariﬁed.
CONCLUDING STATEMENT
Copper plays a central role in a complex network of signaling path-
ways that regulate a host of physiological and pathophysiological
processes. The crucial role of copper in brain and CNS devel-
opment and function was highlighted three decades ago when
the connection was made between infants with MD and copper
deﬁciency (Danks et al., 1972). However, despite its importance,
detailed knowledge of the mechanisms controlling brain cop-
per homeostasis remains limited. Signiﬁcant advances have been
made with the subsequent discovery of key components of the
copper regulatory network. The copper-ATPases, ATP7A and
ATP7B are among these and since their discovery two decades
ago, signiﬁcant progress has been made toward understanding
their pivotal role in normal copper homeostasis. Emerging data
now reveal a complex and varied role for copper in the brain,
and that the copper-ATPases are integral to the regulation and
maintenance of copper-mediated processes within the brain. The
consequences of their malfunction are clearly illustrated by the
severe neurological deﬁcits and neurodegeneration that accom-
pany the disorders of copper transport, MD and WD. More
subtle functional defects in the copper-ATPases or in factors that
regulate their activity and/or stability are likely to contribute
to other neurodegenerative diseases where copper is dysregu-
lated, such as Alzheimer’s, motor neuron and prion diseases.
Given the complexity of the CNS, much remains to be learned
about the role of ATP7A and ATP7B in neurological develop-
ment and neurodegenerative processes. Current ongoing research
into the factors that affect the regulation of their expression,
post-translational modiﬁcation and activity will continue to pro-
vide new insights into their involvement and adaptive capacity
during neuropathological processes associated with aging and
disease.
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